Washington, DC - David Charlot, CEO of CBio, was an invited speaker for a lecture under Patent Examiners Technical Training Program (PETTP) at the Technology Center 1700 of the United States Patents and Trademark Office (USPTO). The event was held on May 1, in Alexandria, VA. PETTP brings academic and industry professionals to discuss innovation in science with patent examiners.
USPTO examiners had the opportunity to listen to our expertise in the development of our innovative technology platform that simplifies complex separation science techniques, enables early detection of disease, and does not compromise performance for biomarker detection in fluids.
About Dr. Charlot
David is an experienced inventor, entrepreneur, and manager with 15 years experience building tools to solve challenges in human health. He is a knowledgeable bioengineer with specialization in automation and systems integration for live cell analysis. He received his PhD in bioengineering from University of California, San Diego and BSc in physics from Delaware State University. David has 18 device patents for DNA and Cell Analysis issued in the US.
As CEO of CBio, David leads a multidisciplinary team to implement his vision to provide access to novel tools clinicians and researchers need to detect treatable disease early. His core passions are providing access to advanced live cell analysis tools and expanding opportunities in STEM education. He believes empowering the next generation of researchers with disruptive technology will spark their creativity and reshape the future of clinical diagnostics.
CBio is a life science tools company equipping researchers and clinicians with tools to help them identify predictive signatures of disease. Our propriety cellPhoresis™ platform enables the study of living cells. Our technology identifies subtle differences between Normal and Abnormal living cells, preserves function, and retains usability for further study.